Suscribirse

Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - 25/09/24

Doi : 10.1016/j.amjmed.2024.06.002 
Cynthia Florêncio de Mesquita a, #, André Rivera b, #, , Beatriz Araújo b, Vitor Leão Durães a, Ivo Queiroz c, Vanessa Henriques Carvalho, MD, PhD d, Tahir Haque, MD e, Taniela M. Bes, MD, PhD f
a Department of Medicine, Federal University of Pernambuco, Recife, Brazil 
b Department of Medicine, Nove de Julho University, São Bernardo do Campo, Brazil 
c Department of Medicine, Catholic University of Pernambuco, Pernambuco, Brazil 
d Department of Medicine, University of Campinas, São Paulo, Brazil 
e Division of General Internal Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, Mass 
f Department of Infectious Diseases, Boston Medical Center, Boston, Mass 

Requests for reprints should be addressed to André Rivera, Department of Medicine, Nove de Julho University, São Bernardo do Campo, BrazilDepartment of MedicineNove de Julho UniversitySão Bernardo do CampoBrazil

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

The efficacy and safety of adjunctive statin therapy in hospitalized patients with coronavirus disease 2019 (Covid-19) remains uncertain.

Methods

We systematically searched Medline, Embase, Cochrane, and ClinicalTrials.gov databases from inception to late April 2024 for randomized controlled trials (RCTs) comparing statin versus no statin use in patients hospitalized with Covid-19. We pooled risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) applying a random-effects model. R version 4.3.1 was used for statistical analyses.

Results

We included 7 RCTs comprising 4,262 patients, of whom 2,645 (62%) were randomized to receive statin therapy. Compared with no statin, statin use significantly reduced case-fatality rate (RR 0.88; 95% CI 0.80-0.98; I2 = 0%). In a time-to-event analysis, we found similar results (HR 0.86; 95% CI 0.75-0.99; I2 = 0%). Statin use also significantly reduced World Health Organization (WHO) scale at 14 days (mean difference -0.27; 95% CI -0.54 to -0.01; I2 = 0%). There was no statistically significant difference between the two groups in length of hospital stay, elevation of liver enzymes, and C-reactive protein levels.

Conclusions

In patients hospitalized with Covid-19, statins significantly reduced case-fatality rate and WHO scale score.

Registration

A prospective register was recorded in International Prospective Register of Systematic Reviews (PROSPERO) with the number CRD42023479007.

El texto completo de este artículo está disponible en PDF.

Keywords : Case-fatality rate, Coronavirus, Covid-19, Statins


Esquema


 Funding: There were no external funding sources for this study.
 Conflict of Interest: All authors declare no conflicts of interest and take full responsibility for the data's reliability and unbiased interpretation.
 Cynthia Florêncio de Mesquita, André Rivera, Beatriz Araújo, Vitor Leão Durães, and Ivo Queiroz Costa Neto are medical students.
 Authorship: CFM: Writing – original draft, Project administration, Methodology, Data curation, Conceptualization. AR: Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. BA: Writing – original draft, Investigation, Formal analysis, Data curation. VD: Writing – original draft, Investigation, Data curation. IQ: Writing – review & editing, Methodology, Investigation, Formal analysis. VHC: Data curation. TH: Writing – review & editing. TMB: Writing – review & editing, Project administration.


© 2024  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 137 - N° 10

P. 966 - octobre 2024 Regresar al número
Artículo precedente Artículo precedente
  • Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
  • Patricia O. Guimarães, Renato D. Lopes, Daniel M. Wojdyla, John H. Alexander, Shaun G. Goodman, Ronald Aronson, Sigrun Halvorsen, Peter Sinnaeve, Dragos Vinereanu, Robert F. Storey, Otavio Berwanger, Stephan Windecker, Roxana Mehran, Christopher B. Granger, Karen P. Alexander, AUGUSTUS Investigators
| Artículo siguiente Artículo siguiente
  • Prior Nonmelanoma Skin Cancer is Associated with Fewer Fractures, More Vitamin D Sufficiency, Greater Bone Mineral Density, and Improved Bone Microarchitecture in Older Adults
  • Michael Thompson, Graeme Jones, Alison Venn, Saliu Balogun, Flavia Cicuttini, Bruna Ragaini, Dawn Aitken

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.